Earnings Feed
Start Free
Home/Filings/4/0001209191-13-038811
4//SEC Filing

Conatus Pharmaceuticals Inc 4

Accession 0001209191-13-038811

CIK 0001383701operating
View on SEC.govCompany Profile

Filed

Jul 31, 8:00 PM ET

Accepted

Aug 1, 7:12 PM ET

Size

14.1 KB

Accession

0001209191-13-038811

Insider Transaction Report

Form 4
Period: 2013-07-30
Conatus Pharmaceuticals IncCNAT
LACASSE LOUIS P
Director
Transactions
  • Other

    Common Stock

    2013-07-30$11.00/sh+12,537$137,907→ 685,937 total(indirect: See footnote)
  • Conversion

    Series B Preferred Stock

    2013-07-30−5,555,556→ 0 total(indirect: See footnote)
    → Common Stock (673,400 underlying)
  • Conversion

    Common Stock

    2013-07-30+673,400→ 673,400 total(indirect: See footnote)
  • Purchase

    Common Stock

    2013-07-30$11.00/sh+123,950$1,363,450→ 809,887 total(indirect: See footnote)
  • Award

    Stock Option (Right to Buy)

    2013-07-30+30,000→ 30,000 total
    Exercise: $11.00Exp: 2023-07-29→ Common Stock (30,000 underlying)
Footnotes (4)
  • [F1]The outstanding shares of Preferred Stock of the Issuer automatically converted into the shares of Common Stock of the Issuer at the closing of the Issuer's initial public offering (the "IPO") at a conversion ratio of 1 share of Common Stock for every 8.25 shares of Preferred Stock, rounded down to the nearest whole number, for no additional consideration.
  • [F2]The shares are held by AgeChem Venture Fund L.P. The general partner of AgeChem Venture Fund, L.P. is AgeChem Financial Inc., for which Mr. Lacasse serves as President. Mr. Lacasse disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
  • [F3]The common stock was acquired upon conversion of a convertible promissory note exempt from the definition of a derivative security because the conversion price did not become fixed until automatic conversion at the time of the closing of the IPO.
  • [F4]The shares subject to this option become exercisable as they vest. One-third of the total number of shares subject to this option vests and becomes exercisable on each anniversary of the grant date, so that the entire number of shares subject to this option becomes fully vested and exercisable on the third anniversary of the grant date.

Documents

1 file

Issuer

Conatus Pharmaceuticals Inc

CIK 0001383701

→
Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001383701

Filing Metadata

Form type
4
Filed
Jul 31, 8:00 PM ET
Accepted
Aug 1, 7:12 PM ET
Size
14.1 KB
View on SEC.gov